Cancer raises blood calcium levels by disrupting the body’s normal calcium balance through several distinct mechanisms. The most common involves tumors releasing a protein that mimics parathyroid hormone, tricking the body into pulling calcium from bones and retaining it in the kidneys. Lung cancer, breast cancer, and multiple myeloma together account for more than half of all cases, with multiple myeloma patients facing the highest rates at 7.5% to 10.2%.
How Tumors Hijack Calcium Regulation
Your body tightly controls blood calcium levels using parathyroid hormone (PTH), which tells bones to release calcium and signals the kidneys to hold onto it rather than filtering it out. Cancer exploits this system in four ways, each involving a different route to the same result: too much calcium flooding the bloodstream.
The most common mechanism, responsible for roughly 80% of cases, involves a protein called PTH-related peptide (PTHrP). Many solid tumors secrete PTHrP directly into the blood, even when they haven’t spread to bone. This protein looks enough like real parathyroid hormone that the body responds the same way: bones break down and release their calcium stores, while the kidneys reabsorb calcium that would normally be excreted in urine. Squamous cell cancers of the lung, head, and neck are particularly likely to produce PTHrP.
When Cancer Spreads to Bone
The second major mechanism happens when cancer physically invades bone tissue. Tumor cells that metastasize to bone don’t dissolve it directly. Instead, they activate osteoclasts, the specialized cells responsible for breaking down bone during normal remodeling. Cancer cells in bone release inflammatory signals, including TNF-alpha and IL-6, that ramp up osteoclast activity far beyond normal levels. As bone tissue is destroyed, the calcium stored within it spills into the bloodstream.
This process is particularly common in breast cancer and multiple myeloma. In myeloma, cancer cells grow within the bone marrow itself, creating pockets of bone destruction called osteolytic lesions. The combination of widespread bone breakdown and the release of local growth factors creates a feedback loop where bone destruction fuels further tumor growth, which drives further destruction.
The Vitamin D Pathway in Lymphoma
A less common but distinct mechanism occurs almost exclusively in lymphomas. In these cancers, tumor cells recruit nearby immune cells called macrophages to produce the active form of vitamin D (calcitriol). Normally, only the kidneys activate vitamin D in carefully regulated amounts. When lymphoma cells trigger uncontrolled vitamin D production outside the kidneys, the excess active vitamin D increases calcium absorption from food in the gut and, to a lesser degree, promotes bone breakdown. This mechanism is more common in large diffuse B-cell lymphomas.
Ectopic Parathyroid Hormone Production
In very rare cases, a tumor produces actual parathyroid hormone rather than the look-alike protein PTHrP. This has been documented in a handful of neuroendocrine tumors and a few other cancers. It’s rare enough that when doctors find elevated PTH alongside cancer, they typically look for a coincidental parathyroid gland problem before suspecting the tumor itself as the source.
What High Calcium Feels Like
Mild hypercalcemia (calcium levels between 10 and 12 mg/dL) often produces no obvious symptoms or only vague fatigue. As levels climb into the moderate range (12 to 14 mg/dL), the effects become hard to ignore. The classic medical shorthand is “stones, bones, abdominal moans, and psychic groans,” which captures the four organ systems hit hardest.
Kidney effects come first for many people: excessive thirst and frequent urination, because high calcium interferes with the kidneys’ ability to concentrate urine. This creates a cycle of dehydration that pushes calcium levels even higher. Kidney stones and, over time, calcium deposits in kidney tissue can develop.
Digestive symptoms include nausea, loss of appetite, constipation, and abdominal pain. The neurological effects range from difficulty concentrating and memory problems at moderate levels to confusion, extreme fatigue, muscle weakness, and even coma when calcium rises above 14 mg/dL. These symptoms often develop gradually, which means they can be mistaken for side effects of cancer treatment or general decline before anyone checks a calcium level.
Which Cancers Carry the Highest Risk
In the United States and Europe, lung cancer, breast cancer, and multiple myeloma are the three most common cancers associated with hypercalcemia. Squamous cell carcinomas of the head and neck, renal cancer, and ovarian cancer follow behind. Among individual cancer types, multiple myeloma has the highest rate by a wide margin: roughly 7.5% to 10.2% of myeloma patients develop elevated calcium. Prostate cancer, despite frequently spreading to bone, has the lowest rate at 1.4% to 2.1%, likely because prostate metastases tend to build abnormal bone rather than destroy it.
How Hypercalcemia Is Treated
The immediate priority is rehydration with intravenous fluids, which helps the kidneys flush excess calcium. Beyond that, the main treatments target osteoclasts to stop the flow of calcium from bone into blood. One class of drugs coats bone surfaces and disrupts osteoclast function, leading to their death within 24 to 48 hours of treatment. The effect lasts roughly a month. A newer approach uses a targeted antibody that blocks the signal osteoclasts need to mature and survive. This takes longer to work (a median of about 9 days) but the effect lasts significantly longer, around 104 days.
These treatments are effective at lowering calcium levels, but they address the symptom rather than the underlying cancer. Lasting control depends on treating the cancer itself.
What Hypercalcemia Means for Prognosis
The development of hypercalcemia in cancer generally signals advanced disease, and the statistics reflect that. Median survival after diagnosis of cancer-related hypercalcemia is roughly 52 to 68 days across multiple studies. About 50% of patients die within 30 days, and up to 75% die within three months. Only about 25% survive a year.
These numbers hold even when calcium levels are successfully brought back to normal, which underscores that hypercalcemia is a marker of how advanced the cancer has become rather than a direct cause of death in most cases. The calcium itself can cause organ failure if left untreated, but correcting it alone does not change the trajectory of the underlying disease. For patients with otherwise treatable cancers, however, recognizing and managing hypercalcemia quickly can prevent dangerous complications and buy critical time for cancer-directed therapy to work.